TCM
MCRB icon

TimesSquare Capital Management’s Seres Therapeutics MCRB Stock Holding History

TimesSquare Capital Management’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-24,554
Closed -$14.3M – 242
2016
Q2 		$14.3M Sell
24,554
-115
-0.5% -$67.5K 0.09% 209
2016
Q1 		$13.1M Sell
24,669
-331
-1% -$173K 0.09% 209
2015
Q4 		$17.5M Buy
25,000
+2,750
+12% +$1.81M 0.11% 206
2015
Q3 		$13.2M Buy
22,250
+1,745
+9% +$1.42M 0.08% 215
2015
Q2 		$17M Buy
+20,505
New +$17.9M 0.09% 217

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

TimesSquare Capital Management's MCRB Position: Q3 2016 in Review

TimesSquare Capital Management sold out of Seres Therapeutics (MCRB) in Q3 2016, closing a stake of 24,554 shares — an estimated $14.3M sold.

TimesSquare Capital Management first reported a position in MCRB in Q2 2015 and held it in 5 quarters. The position peaked at $17.5M in Q4 2015. 94 funds tracked by Wall St. Rank hold MCRB as of Q3 2016.

  • TimesSquare Capital Management reported no remaining Seres Therapeutics position as of Q3 2016 after selling out during the quarter.
  • TimesSquare Capital Management sold 24,554 Seres Therapeutics shares in Q3 2016, an estimated $14.3M.
  • TimesSquare Capital Management first reported a position in Seres Therapeutics in Q2 2015 and held it in 5 quarters.
  • TimesSquare Capital Management's Seres Therapeutics position peaked at $17.5M in Q4 2015.
  • 94 funds tracked by Wall St. Rank held Seres Therapeutics as of Q3 2016.

Based on TimesSquare Capital Management's 13F filing for Q3 2016, filed 10 Nov 2016.